文献速递中毒与环境急症重症综合管理与镇静镇痛

伊利诺伊州合成大麻素相关凝血病暴发

An Outbreak of Synthetic Cannabinoid-Associated Coagulopathy in Illinois.
PubMed 文献 · N Engl J Med · 2018-01-01
一句话结论合成大麻素掺入超级华法林可致严重凝血病,34例中多数经维生素K1治疗出血控制,1例死于自发性颅内出血。

2018年3–4月美国伊利诺伊州超过150例患者因凝血病和出血素质就诊,患者血清和药物样本初步检测显示溴敌隆为可能掺杂物。本研究回顾了2018年3月28日至4月21日期间入住伊利诺伊州皮奥里亚市圣弗朗西斯医疗中心并符合合成大麻素相关凝血病诊断标准的成人病例系列。共识别34例患者、45次住院,15例完成确证性抗凝剂中毒检测,15例均确认超级华法林中毒。所有34例口服维生素K1,23例(68%)另经静脉给药,19例(56%)输注新鲜冰冻血浆,5例(15%)输注红细胞,1例使用四因子凝血酶原复合物浓缩物;1例死于自发性颅内出血并发症。

要点

  • 合成大麻素相关凝血病暴发中,34例患者共45次住院,15例完成确证检测者全部确认超级华法林中毒。
  • 确证检测中溴敌隆阳性15例(100%)、敌鼠隆5例(33%)、溴鼠隆2例(13%)、华法林1例(7%)。
  • 常见表现:肉眼血尿19例(56%)、腹痛16例(47%);腹痛行CT检查发现肾脏异常12例。
  • 所有34例口服维生素K1,23例(68%)另经静脉给药;红细胞输注5例(15%),新鲜冰冻血浆19例(56%)。
  • 1例死于自发性颅内出血并发症。

适用人群与场景

  • 2018年3月28日至4月21日入住伊利诺伊州皮奥里亚市圣弗朗西斯医疗中心的成人患者,符合合成大麻素相关凝血病诊断标准。
  • 2018年3–4月伊利诺伊州医院就诊的凝血病和出血素质患者。

诊断标准与关键阈值

  • 符合用于诊断合成大麻素相关凝血病的标准。

处置流程与药物剂量

  • 所有34例口服维生素K1(植物甲萘醌)。
  • 23例(68%)另经静脉给予维生素K1。
  • 5例(15%)输注红细胞。
  • 19例(56%)输注新鲜冰冻血浆。
  • 1例使用四因子凝血酶原复合物浓缩物。
  • 确证性抗凝剂中毒检测由主治医师酌情开具。

红旗征与不能漏的情况

  • 出血素质(如肉眼血尿、腹痛)需警惕合成大麻素相关凝血病。
  • 自发性颅内出血可致死(1例死于该并发症)。

研究设计与关键结果

  • 研究类型:病例系列;地点:伊利诺伊州皮奥里亚市圣弗朗西斯医疗中心;时间:2018年3月28日至4月21日。
  • 共识别34例合成大麻素相关凝血病患者,涉及45次住院。
  • 34例中15例完成确证性抗凝剂检测,15例均确认超级华法林中毒。
  • 抗凝剂检测阳性:溴敌隆15例(100%)、敌鼠隆5例(33%)、溴鼠隆2例(13%)、华法林1例(7%)。
  • 就诊常见症状:肉眼血尿19例(56%)、腹痛16例(47%)。
  • 腹痛行CT检查发现肾脏异常12例。
  • 治疗:口服维生素K1 34例(100%),静脉维生素K1 23例(68%),红细胞输注5例(15%),新鲜冰冻血浆19例(56%),四因子凝血酶原复合物浓缩物1例。
  • 1例死于自发性颅内出血并发症。

证据类型、等级与局限

  • 证据类型:病例系列。
  • 局限:特定合成大麻素化合物未知;原文未报告其他局限性。

对床旁实践的改变

  • 作者认为,合成大麻素的超级华法林掺杂物可导致临床显著凝血病。
  • 作者指出,在该系列中大多数以出血素质就诊的病例,症状经维生素K1替代治疗得到控制。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In March and April 2018, more than 150 patients presented to hospitals in Illinois with coagulopathy and bleeding diathesis. Area physicians and public health organizations identified an association between coagulopathy and synthetic cannabinoid use. Preliminary tests of patient serum samples and drug samples revealed that brodifacoum, an anticoagulant, was the likely adulterant.

METHODS: We reviewed physician-reported data from patients admitted to Saint Francis Medical Center in Peoria, Illinois, between March 28 and April 21, 2018, and included in a case series adult patients who met the criteria used to diagnose synthetic cannabinoid-associated coagulopathy. A confirmatory anticoagulant poisoning panel was ordered at the discretion of the treating physician.

RESULTS: A total of 34 patients were identified as having synthetic cannabinoid-associated coagulopathy during 45 hospitalizations. Confirmatory anticoagulant testing was performed in 15 of the 34 patients, and superwarfarin poisoning was confirmed in the 15 patients tested. Anticoagulant tests were positive for brodifacoum in 15 patients (100%), difenacoum in 5 (33%), bromadiolone in 2 (13%), and warfarin in 1 (7%). Common symptoms at presentation included gross hematuria in 19 patients (56%) and abdominal pain in 16 (47%). Computed tomography was performed to evaluate abdominal pain and revealed renal abnormalities in 12 patients. Vitamin K1 (phytonadione) was administered orally in all 34 patients and was also administered intravenously in 23 (68%). Red-cell transfusion was performed in 5 patients (15%), and fresh-frozen plasma infusion in 19 (56%). Four-factor prothrombin complex concentrate was used in 1 patient. One patient died from complications of spontaneous intracranial hemorrhage.

CONCLUSIONS: Our data indicate that superwarfarin adulterants of synthetic cannabinoids can lead to clinically significant coagulopathy. In our series, in most of the cases in which the patient presented with bleeding diathesis, symptoms were controlled with the use of vitamin K1 replacement therapy. The specific synthetic cannabinoid compounds are not known.

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Kelkar AH, Smith NA, Martial A, et al. An Outbreak of Synthetic Cannabinoid-Associated Coagulopathy in Illinois. N Engl J Med. 2018. PMID: 30280655. doi:10.1056/NEJMoa1807652

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。